|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATAD3B |
Gene summary for ATAD3B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATAD3B | Gene ID | 83858 |
| Gene name | ATPase family AAA domain containing 3B | |
| Gene Alias | AAA-TOB3 | |
| Cytomap | 1p36.33 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q5T9A4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83858 | ATAD3B | LZE7T | Human | Esophagus | ESCC | 1.98e-04 | 2.48e-01 | 0.0667 |
| 83858 | ATAD3B | LZE24T | Human | Esophagus | ESCC | 2.92e-06 | 1.83e-01 | 0.0596 |
| 83858 | ATAD3B | P1T-E | Human | Esophagus | ESCC | 1.50e-07 | 3.12e-01 | 0.0875 |
| 83858 | ATAD3B | P2T-E | Human | Esophagus | ESCC | 2.91e-09 | 1.82e-01 | 0.1177 |
| 83858 | ATAD3B | P4T-E | Human | Esophagus | ESCC | 2.36e-15 | 4.98e-01 | 0.1323 |
| 83858 | ATAD3B | P5T-E | Human | Esophagus | ESCC | 6.42e-10 | 1.98e-01 | 0.1327 |
| 83858 | ATAD3B | P8T-E | Human | Esophagus | ESCC | 6.35e-15 | 2.91e-01 | 0.0889 |
| 83858 | ATAD3B | P9T-E | Human | Esophagus | ESCC | 1.15e-08 | 1.20e-01 | 0.1131 |
| 83858 | ATAD3B | P10T-E | Human | Esophagus | ESCC | 4.71e-08 | 1.63e-01 | 0.116 |
| 83858 | ATAD3B | P11T-E | Human | Esophagus | ESCC | 1.81e-03 | 1.72e-01 | 0.1426 |
| 83858 | ATAD3B | P12T-E | Human | Esophagus | ESCC | 9.75e-06 | 1.18e-01 | 0.1122 |
| 83858 | ATAD3B | P15T-E | Human | Esophagus | ESCC | 8.53e-15 | 1.78e-01 | 0.1149 |
| 83858 | ATAD3B | P16T-E | Human | Esophagus | ESCC | 7.11e-10 | 9.71e-02 | 0.1153 |
| 83858 | ATAD3B | P20T-E | Human | Esophagus | ESCC | 1.37e-14 | 3.00e-01 | 0.1124 |
| 83858 | ATAD3B | P21T-E | Human | Esophagus | ESCC | 3.14e-19 | 2.34e-01 | 0.1617 |
| 83858 | ATAD3B | P22T-E | Human | Esophagus | ESCC | 3.52e-03 | 4.05e-02 | 0.1236 |
| 83858 | ATAD3B | P23T-E | Human | Esophagus | ESCC | 4.26e-16 | 1.99e-01 | 0.108 |
| 83858 | ATAD3B | P24T-E | Human | Esophagus | ESCC | 1.27e-14 | 1.07e-01 | 0.1287 |
| 83858 | ATAD3B | P26T-E | Human | Esophagus | ESCC | 1.01e-04 | 4.49e-02 | 0.1276 |
| 83858 | ATAD3B | P27T-E | Human | Esophagus | ESCC | 3.91e-24 | 1.75e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATAD3B | SNV | Missense_Mutation | novel | c.699N>A | p.Phe233Leu | p.F233L | Q5T9A4 | protein_coding | tolerated(1) | benign(0.009) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| ATAD3B | SNV | Missense_Mutation | c.1468G>A | p.Asp490Asn | p.D490N | Q5T9A4 | protein_coding | tolerated(0.07) | benign(0.134) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ATAD3B | SNV | Missense_Mutation | novel | c.1854N>C | p.Trp618Cys | p.W618C | Q5T9A4 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ATAD3B | SNV | Missense_Mutation | rs752824611 | c.1912N>T | p.Arg638Trp | p.R638W | Q5T9A4 | protein_coding | tolerated_low_confidence(0.11) | benign(0) | TCGA-A6-A567-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| ATAD3B | SNV | Missense_Mutation | rs367992193 | c.917N>A | p.Arg306Gln | p.R306Q | Q5T9A4 | protein_coding | tolerated(0.12) | benign(0.402) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATAD3B | SNV | Missense_Mutation | rs750391230 | c.1213G>A | p.Gly405Ser | p.G405S | Q5T9A4 | protein_coding | deleterious(0.03) | probably_damaging(0.98) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| ATAD3B | SNV | Missense_Mutation | rs777121713 | c.625N>A | p.Glu209Lys | p.E209K | Q5T9A4 | protein_coding | tolerated(0.06) | probably_damaging(0.993) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ATAD3B | SNV | Missense_Mutation | c.1024N>T | p.Arg342Trp | p.R342W | Q5T9A4 | protein_coding | deleterious(0.01) | possibly_damaging(0.696) | TCGA-AG-3731-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | PR | |
| ATAD3B | SNV | Missense_Mutation | c.911G>A | p.Ser304Asn | p.S304N | Q5T9A4 | protein_coding | tolerated(0.31) | benign(0.171) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
| ATAD3B | SNV | Missense_Mutation | rs144497634 | c.251C>T | p.Thr84Met | p.T84M | Q5T9A4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-DC-6682-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |